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ABSTRACT 44 
The diagnosis, treatment and prevention of infectious diseases in older adults in 45 
long-term care facilities (LTCFs), particularly nursing facilities, remain a challenge for all health 46 
providers who care for this population. In this review, the authors provide updated information 47 
on the currently most important issues of infectious diseases in LTCFs. With the increasing 48 
prescribing of antibiotics in older adults, particularly in LTCFs, the topic of antibiotic 49 
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points on the clinical relevance, clinical presentation, diagnostic approach, therapy, and 51 
prevention are discussed for skin and soft tissue infections, infectious diarrhea (Clostridium 52 
difficile and norovirus infections), bacterial pneumonia, and urinary tract infection as well as 53 
some of the newer approaches to preventive interventions in the LTCF setting. 54 
 55 
(Abstract: 127 words) 56 
_________________________________________________________ 57 
.INTRODUCTION 58 
Many of the clinical challenges and differences in epidemiology, pathogenesis, 59 
diagnostic approach, treating, and preventing infections in the older adult population have 60 
been recently described. (1) However, among older adults, there is a subset of individuals who 61 
add another dimension of complexity, difficulties and challenges in managing infections, i.e., 62 
those who reside in long-term care facilities (LTCFs), or more specifically, nursing homes, which 63 
are now more commonly referred to as nursing facilities (NFs). The 15,600 NFs in the United 64 
States provide medical and residential care for 1.4 million persons on a daily basis. Each year, 65 
3.2 million persons reside in one of these facilities for some period of time. (2,3) Although LTCFs 66 
may also refer to rehabilitation centers, assisted living facilities and other forms of residential 67 
care, in this paper the term LTCF will be referring to NF and thus both terms may be used 68 
interchangeably. The authors will focus on providing an update on the approach to the most 69 
important infectious diseases as well as the challenges clinicians encounter in diagnosing, 70 
treating and preventing infections in older adults residing in an LTCF/NF. A brief summary on 71 
managing infection outbreaks in LTCFs can be found in a recent publication (1) and thus will not 72 
be discussed in this review.  73 
Hospitalized patients include a wide spectrum of age groups and diseases/disorders 74 
needing acute (immediate) diagnosis and management, and generally have a short stay of less 75 
than a week. In contrast, the population in LTCFs/NFs is almost exclusively those beyond age 65 76 
(average age about 80-85 years); suffer from multiple chronic diseases/disorders (with 77 
occasional acute exacerbations), physical disability, cognitive impairment, and functional 78 
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the LTCF/NF for the rest of their lives. Consequently, the goals of care, approach, resources, 80 
environment and staffing in an LTCF/NF may be very dissimilar to those of an acute care facility. 81 
Standard hospital care in a ward setting generally requires a registered nurse (RN) to patient 82 
ratio of 1:5; however, the LTCF: patient/resident ratio is 1:25. Acute care hospitals have 83 
physicians making daily rounds on their patients with onsite availability of laboratory and 84 
imaging studies, whereas LTCFs/NFs usually have no immediate access to such tests and 85 
physicians generally see the resident once a month (more often if the resident is not clinically 86 
well). It is also well known that infection is a major health issue in residents of LTCF/NFs and 87 
that the diagnosis of an infection may be challenging in this population, given the atypical 88 
presentation commonly seen in older adults with infection, which sometimes includes a lack of 89 
a febrile response. (1) With these major differences between a patient in an acute hospital 90 
setting versus a resident in an LTCF/NF, there is a substantial challenge in the approach to the 91 
clinical and laboratory diagnosis, treatment, and prevention of serious infections in this setting.  92 
ANTIBIOTIC STEWARDSHIP 93 
Introduction 94 
Approximately 75% of residents who stay in a NF for 6 months or longer will receive at 95 
least one course of antibiotics. (4-6) Over half of the antibiotic courses initiated in NFs are 96 
unnecessary and, even when necessary, the antibiotics prescribed are often excessively 97 
broad-spectrum or administered for a duration longer than necessary for treatment of the 98 
underlying infection. The overuse and misuse of antibiotics in NFs are major causes of adverse 99 
drug events and future infections such as those caused by Clostridium difficile and 100 
antibiotic-resistant bacteria. Once acquired by a resident, C. difficile and/or antibiotic-resistant 101 
bacteria may then be spread to other residents and to patients in hospitals when resident 102 
illness requires a higher level of care.  103 
Improving the quality of antibiotic prescribing in healthcare settings increasingly relies 104 
on development and expansion of antibiotic stewardship programs (ASPs) which are 105 
characterized by coordinated efforts: 1) to monitor patterns of antibiotic use and 106 
antibiotic-related outcomes and 2) to oversee identification and implementation of strategies 107 
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significant reductions in use of targeted antibiotics, reductions in C. difficile and certain types of 109 
multidrug-resistant organisms (MDROs), and significant cost savings. (8) Expansion of ASPs into 110 
other healthcare settings has been recommended by policy stakeholders (9) but their uptake in 111 
NFs remains limited. (6,7) Nevertheless, this situation is poised to change rapidly with the 112 
recent release of regulations that will require NFs to have ASPs in place by November of 2017. 113 
(10)  114 
Barriers to Antibiotic Stewardship 115 
ASPs in hospitals and NFs share common goals although their structure and process are 116 
quite different. (7) ASPs in hospitals are typically organized around a team of individuals with 117 
expertise in infectious diseases, pharmacodynamics/pharmacokinetics and informatics. (9) 118 
Stewardship programs in NFs are most commonly directed by the facility infection 119 
preventionists or director of nursing. The medical director and pharmacist are actively engaged 120 
in ASPs in less than 50% of NFs and involvement of individuals with formal infectious disease 121 
training is present in less than 15% of facilities. (7) Most hospitals employ mature and 122 
sophisticated electronic record systems that permit efficient tracking and reporting of antibiotic 123 
utilization and antibiotic-related outcomes. However, adoption of electronic health record 124 
systems has been slow in NFs, and most still rely on cumbersome manual methods to track and 125 
report process and outcome measures. The most effective antibiotic improvement methods in 126 
hospitals, including prior authorization and post-prescriptive review and feedback, can be quite 127 
effort-intensive. (9) While similar strategies have proven effective in NFs, (11) most facilities 128 
lack the resources and expertise to sustain these types of efforts. Consequently, efforts to 129 
improve the quality of antibiotic prescribing in NFs have primarily relied upon education, 130 
dissemination of guidelines and introduction of decision-support tools. (6)  131 
 132 
Implementing an ASP 133 
While implementing an ASP in a NF can be a daunting task, tools developed by the 134 
Centers for Disease Control and Prevention (CDC) (12,13) can help facilities structure their 135 
initial planning and implementation efforts (Table 1). Support from facility leadership, assembly 136 
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structural resources that NFs should have in place when first embarking on development of an 138 
ASP. While it is unlikely that most NFs will have access to an ASP leader with specific antibiotic 139 
stewardship expertise, individuals with an understanding of facility clinical operations and data 140 
systems as well as experience with quality improvement activities should be accessible in most 141 
facilities. In most NFs, the infection preventionist or director of nursing are the individuals in 142 
the best position to assume this key leadership role although other individuals, such as the NF 143 
pharmacist, may also be appropriate. The medical director and director of nursing, even if they 144 
are not the designated ASP leaders, can assume a critical role in growing the facility ASP by 145 
publicly affirming its importance and supporting improvement efforts. 146 
Tracking and reporting antibiotic utilization and antibiotic-related outcomes (e.g., C. 147 
difficile and MDROs) is a core activity recommended by the CDC (12) and will be required under 148 
new regulations. (10) NFs currently perform infection surveillance and tracking residents that 149 
experience a change-in-condition, particularly those receiving antibiotics, as a routine practice 150 
in NFs. (14) Adapting these existing processes to track antibiotic utilization and related 151 
outcomes should, therefore, be feasible in most NFs. At a minimum, facilities should 152 
periodically assess antibiotic utilization in the facility cross-sectionally (e.g., the number of 153 
residents on antibiotics during a given day, week, or month). In order to monitor the effects of 154 
improvement interventions and detect aberrant prescribing patterns, NFs should ideally track 155 
antibiotic starts and/or antibiotic days of therapy prospectively. Stratifying tracking measures 156 
by indication (e.g., urinary tract infection [UTI]) and antibiotic class (e.g., fluoroquinolones) can 157 
help facilities better ascertain conditions in need of focused attention and follow the effects of 158 
condition-specific interventions. Supplementing utilization measures with assessments of 159 
appropriateness (e.g., proportion of monthly antibiotic courses meeting explicit criteria or 160 
proportion of monthly antibiotic courses exceeding 7 days (15)) can provide additional insights 161 
into opportunities for improvement.  162 
Once an ASP team and a system for monitoring antibiotic utilization are in place, NFs 163 
should focus on developing policies and procedures that encompass prescribing etiquette (e.g., 164 
providing the indication, drug, dose and duration with every antibiotic order), clinical 165 
indications for diagnostic testing,
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preferred agents for treating commonly encountered infections. Education of facility staff and 167 
providers as well as resident families (16) is another foundational antibiotic stewardship 168 
strategy that has been shown to be effective in reducing inappropriate antibiotic use in NFs. 169 
Introduction of training and tools focused on improving resident assessments and 170 
interdisciplinary communication of resident change-in-condition have been associated with 171 
significant reductions in antibiotic utilization in several studies (16) and may have benefits in 172 
other areas such as reducing hospital admissions. Given the outsized role that suspected UTI 173 
plays in antibiotic prescribing in NFs, (6,17) implementation of protocols that restrict urine 174 
testing to residents with a high probability of having a UTI and similarly designed protocols to 175 
limit antibiotic therapy in residents without clear symptoms and signs of UTI (18,19) would 176 
appear to offer a good return on investment. Strategies focused on promotion of self-directed 177 
stewardship, in which prescribers are trained and/or prompted to engage in review of 178 
empirically initiated antibiotics and modify the therapeutic dose, spectrum and/or duration 179 
when appropriate (“antibiotic timeout”), has been implemented successfully in hospitals (20) 180 
and implementation of a checklist tool to promote this practice in NFs was associated with a 181 
significant reduction in systemic antibiotic use in intervention facilities in one study. (21) Other 182 
improvement strategies, such as introduction of a facility-specific antibiogram and a 183 
pharmacist-led post-prescriptive audit and feedback, can be very effective but may require 184 
expertise and resources that are not widely available in most NFs. (6,7)  185 
 186 
Future Directions 187 
The emerging crisis in antibiotic resistance will require a concerted effort to improve 188 
antibiotic stewardship across all healthcare settings. Considerable progress has been made in 189 
our understanding of the extent and determinants of inappropriate antibiotic use in NFs. While 190 
there is accumulating evidence that interventions focused on processes (e.g., urine testing) 191 
associated with the initial antibiotic decision can reduce unnecessary antibiotic use, there 192 
remains a critical need to identify the effectiveness of interventions that target post-prescribing 193 
decision-making (e.g., review and de-escalation) and how these interventions can be delivered 194 
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stewardship interventions with fidelity and sustain them over time, particularly in NFs with 196 
limited quality improvement resources. Finally, there is a need for studies that evaluate the 197 
effects of stewardship interventions on facility and resident outcomes, including healthcare 198 
costs as well as rates of infections caused by C. difficile and multidrug-resistant bacteria. 199 
 200 
SKIN AND SOFT TISSUE INFECTION (SSTI) 201 
Clinical Relevance 202 
SSTIs are the third most common infection diagnosed in LTCF residents. In surveys of 203 
European and US Veterans Affairs LTCFs, it is suggested that ~ 22% of infections are due to SSTI. 204 
(22,23) Routine infection surveillance in LTCF does not require the monitoring of all SSTI, so the 205 
prevalence of less severe infections may not be known. (24) However, in Europe, it has been 206 
estimated that bacterial infections such as cellulitis, soft tissue and wound infections account 207 
for 87.4% of SSTI. (22) Fungal infections (8.3%) followed by herpes simplex or herpes zoster 208 
infections (2.4%) and scabies (1.9%) account for the remainder. (22)  209 
 210 
Risk Factors for SSTI in Older adults 211 
Increased exposure to pathogens and conditions that promote changes in patient 212 
normal flora contribute to risk of SSTIs. Shared living space exposes residents to various 213 
pathogens. Use of antibiotics and corticosteroids contribute to the overgrowth of bacteria and 214 
fungi. Waning immunity is associated with reactivation of latent herpes infections in LTCF 215 
residents; 10,000-20,000 cases of herpes zoster occur annually. (25,26) 216 
Primary bacterial infections are frequently due to bacteria that asymptomatically 217 
colonize human skin and mucosa, such as Staphylococcus aureus and group A beta-hemolytic 218 
streptococci (GABHS). These bacteria can be easily spread to other residents and staff; 219 
outbreaks have been reported with high attack and fatality rates. Outbreaks of acute bacterial 220 
conjunctivitis may occur due to these pathogens as well. Epidemics of viral conjunctivitis due to 221 
adenovirus are also reported; spread is facilitated by contamination of ophthalmologic 222 
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Pre-existing wounds can become secondarily infected by bacteria transferral from other 224 
patients via the hands of healthcare personnel or from the environment. (25,26) Breaks in skin 225 
can occur as a consequence of thinning of skin with age, pressure due to decreased mobility, 226 
maceration associated with incontinence, ischemia due to reduced blood flow, edema, and 227 
device use. Pressure ulcer risk increases with length of stay; it is estimated that one-fifth of 228 
LTCF residents will acquire an ulcer within 2 years. Almost 6% of pressure ulcers in LTCF 229 
residents will become infected. (25,26) These infections are typically polymicrobial involving 230 
aerobic and anaerobic flora including Escherichia coli, Proteus species, Pseudomonas species, 231 
staphylococci, enterococci, anaerobic streptococci, Bacteroides species, and Clostridium 232 
species. (25,26) 233 
 234 
Clinical Presentation 235 
Primary bacterial SSTIs can be categorized as erythematous without purulence or with 236 
purulence (Table 2). Infections that involve deeper structures such as fascia occur less often 237 
and are typically more severe. (25-27) Non-bacterial superficial mucocutaneous infections also 238 
occur in LTCF due to Candida and tinea species and dermatophyte (tinea) infections (Table 2). 239 
Tinea ungiuum has been reported to occur in 10-57% and tinea pedis in 10-34% of residents. 240 
Rashes due to scabies [Sarcoptes scabiei], lice [Pediculus humanus capitus, P. humanus corporis, 241 
Phthirus pubis] and bedbugs [Cimex lectularius] and reactivation of herpesvirus infections 242 
[herpes simplex and herpes zoster] also occur. Scabies has been reported in 3.3% of LTCF 243 
residents with an attack rate of ~70%. (25,26) 244 
 245 
Diagnostic Approach 246 
Initial evaluation of possible SSTI should focus on the acuity of onset of the SSTI and 247 
whether symptoms and signs of systemic illness are present (27,29,Table 2). Pain out of 248 
proportion to clinical findings might suggest herpetic infection or necrotizing fasciitis. 249 
Distribution or location of skin lesions may suggest a diagnosis such as involvement of 250 
intertriginous areas (Candida or tinea infection), dermatomes (herpes zoster), nape of the neck 251 
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erythema, pustules, blisters, ulcerations, size, depth and rate of spread should be described.  253 
If the skin lesions have a characteristic appearance, then further diagnostic testing may 254 
not be necessary. Painful or pruritic vesicles or ulcerations involving nasolabial, genital, or rectal 255 
skin and mucosa suggests herpes simplex, while a dermatomal distribution that does not cross 256 
the midline is diagnostic for herpes zoster. (25,26) Typical scabies presents with pruritis, 257 
intertrigenous rashes, and burrows; these features may be absent in older patients. Crusted 258 
scabies can be more typical in this population, and the diagnosis is made only when usual 259 
features are seen in visitors or healthcare workers. (25,26) Head and pubic lice may be found 260 
crawling in their respective hair bearing areas; their eggs (nits) may be found at the base of hair 261 
follicles. In the case of body lice, the louse or nits are found in the seams of clothing. Acquisition 262 
of bed bugs in the healthcare setting is rare as furniture in this setting is easily cleaned and 263 
disinfected. Red pruritic nodules may be noted in a linear distribution. Bed bugs are rarely 264 
found on the patient; they infest clothing, mattresses, and overstuffed furniture. When they are 265 
seen, adult bed bugs run rapidly and have a flat, red brown apple seed appearance. (25,26,29)  266 
If the clinical appearance is atypical, the patient is severely ill, or is not responding to 267 
empirical therapy then further diagnostic studies are appropriate. Scrapings for fungal 268 
potassium hydroxide (KOH) smear, Tzanck smear and viral polymerase chain reaction (PCR) for 269 
herpesviruses, or for ectoparasites, eggs, and feces can be done. (25-27,29) Deep cultures of 270 
pus, aspirates, or tissue are recommended to confirm the cause of the infection and 271 
antimicrobial susceptibilities. Swabs of superficial ulcers likely reflect colonization and not the 272 
true cause of infection. MDROs frequently colonize or infect LTCF residents and can influence 273 
treatment choices. (22) In the US, LTCF residents, overall rates of colonization have varied for 274 
methicillin-resistant S. aureus (MRSA) (11-59%), 1-19% for vancomycin-resistant enterococci 275 
(VRE), and 23-51% for multidrug resistant gram-negative organisms. (5) Many residents are 276 
colonized with more than one organism, and new acquisitions may be frequent. (5) 277 
 278 
Therapy 279 
Residents with possible bacterial infections who do not have symptoms or signs of 280 
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directives warrant aggressive care then transfer to hospital is appropriate for more intensive 282 
monitoring, urgent imaging and surgical intervention. 283 
One important consideration for SSTI is when to begin antibacterial therapy. For SSTI, 284 
minimum criteria have been established to initiate an antibiotic including at least one of the 285 
following: 1) pus present at a wound, skin, or soft tissue site or 2) at least two
 293 
 of the following: 286 
fever or new or worsening redness, tenderness, warmth, or swelling at the suspected site. 287 
These criteria do not apply to non-bacterial infections or deep tissue or bone infection. 288 
Non-infectious causes such as burns, thromboembolic disease, and gout should be considered. 289 
(29) If a decision is made to begin treatment, the most likely underlying etiologies of the skin 290 
lesions, the clinical stability of the patient, and the route of antimicrobial administration should 291 
be considered in addition to risks for MDRO (Table 2).  292 
Prevention  294 
Prevention of SSTI should focus on prevention of wounds by alleviating their underlying 295 
cause and using good technique to keep wounds clean. Screening for neuropathy and use of 296 
appropriate footwear in diabetics is essential. Patients who are immobile should have optimal 297 
pressure relief with appropriate bedding and wheelchair cushions. Macrovascular disease 298 
should be evaluated and blockages relieved when feasible. Edema should be controlled with 299 
medications and compression wraps if venous insufficiency is present. Adherence to infection 300 
control procedures, such as hand hygiene and glove use, to prevent the spread of pathogens is 301 
essential. Limiting the use unnecessary and overly broad antibiotics may limit overgrowth of 302 
Candida species. Vaccination may also reduce herpes zoster infection. (25,26) 303 
 304 
INFECTIOUS DIARRHEA
Clinical Relevance 306 
  305 
Bacteria, viruses and, occasionally, protozoa may all cause outbreaks of infectious 307 
diarrhea in LTCFs. Discussed in detail below, C. difficile is the most important and most common 308 
bacterial cause of nosocomial diarrhea in this setting. Other bacterial pathogens include 309 
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Escherichia coli. (29) Additionally, ingestion of food contaminated with enterotoxins produced 311 
by S. aureus, C. perfringens and Bacillus cereus may also lead to outbreaks of nausea and 312 
vomiting. A wide array of viruses from the families Caliciviridae and Adenoviridae as well as 313 
enterovirus and rotavirus may cause gastroenteritis among nursing home residents. Of these, 314 
norovirus, a member of the family Caliciviridae, is globally the leading cause of acute 315 
gastroenteritis and merits further discussion below. Finally, protozoa such as Giardia, 316 
Cryptosporidium and Cyclospora may cause diarrheal outbreaks in institutional settings, 317 
including those that care for older adults.  318 
 319 
C. difficile 320 
Older adults are at increased risk for infections caused by C. difficile, a gram-positive 321 
spore-forming bacillus. (30-31) In 2010, over 90% of deaths due to C. difficile infection (CDI) 322 
were in adults aged ≥ 65 years. Age-specific risk factors for CDI include changes to the gut 323 
microbiome and immunosenescence. Both aging and residence in an LTCF correlate with a less 324 
diverse gut microbiome at baseline. Subsequent exposure to antibiotics causes further 325 
disruption to the gut microbiome, rendering people exposed to C. difficile spores vulnerable to 326 
infection for up to 90 days following completion of their antibiotic. (32) Once ingested by a 327 
vulnerable host, C. difficile spores germinate in the intestine to become toxin-producing 328 
vegetative bacteria. Robust antibody production against C. difficile toxins correlates with a 329 
decreased risk for CDI and for recurrent disease. Older adults unable to mount a robust 330 
immune response may have diminished capacity to neutralize the effects of C. difficile toxins, 331 
correlating with both increased disease severity and risk of recurrent disease. Moreover, CDI 332 
among LTCF residents is more severe and associated with more recurrent infection compared 333 
to older adults living in a community setting with CDI. (33)  334 
 335 
Clinical Presentation  336 
CDI presents as watery diarrhea, sometimes accompanied by abdominal cramping and 337 
discomfort. While some patients may mount a fever, nausea and vomiting are not typical 338 
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blood count of 15,000 cells/μL and a creatinine level less than 1.5 fold of the premorbid level. 340 
Severe disease, with a white blood cell count of >15,000 cells/μL or serum creatinine 1.5 times 341 
greater than the premorbid level, is best managed in acute care settings that can offer fluid 342 
resuscitation, electrolyte replacement and, for severe cases, parental therapy and possible 343 
colectomy. (32) Severe disease may occasionally present with an ileus, leading to a clinical 344 
presentation of abdominal pain and distention without diarrhea. These individuals appear toxic, 345 
with hemodynamic instability.  346 
Following an initial episode of CDI, 20-30% of adults develop recurrent disease, most 347 
often within 1-2 weeks of completing therapy. Recurrent CDI is not due to resistance but rather 348 
to reexposure of a vulnerable host to C. difficile spores. These may be the same strain causing 349 
the initial infection (relapse) or a new strain of C. difficile (reinfection). In 2000, one study 350 
reported that among 93 people with recurrent CDI, relapse with the same strain caused 351 
approximately 50% of cases while reinfection with new strains caused the remainder of cases. 352 
(31) The risk for recurrence increases with age and, not surprisingly, with antibiotic exposure. 353 
Medications that suppress gastric acid production represent a potentially modifiable risk factor 354 
for recurrent disease. (34) In a retrospective study of 754 hospitalized patients with CDI, the 355 
authors found a hazard ratio of 1.5 (95% confidence interval (CI), 1.1 to 2.0) for recurrent CDI 356 
among those receiving proton pump inhibitor therapy; less than 50% of those patients had an 357 
indication for taking a proton pump inhibitor. (34)  358 
 359 
Diagnostic Approach 360 
Clinical criteria for CDI are 3 or more unformed stools within 24 hours and a stool test 361 
positive for toxigenic C. difficile or demonstration of pseudomembranous colitis. (32,35) The 362 
approach and selection of specific tests to support a laboratory diagnosis of CDI remains an 363 
area of controversy. A guidance document from the European Society of Clinical Microbiology 364 
and Infectious Diseases recommends a 2-step algorithm as no single commercial test has a 365 
sufficient positive predicative value when the prevalence of CDI is low. (36) Regardless of the 366 
diagnostic tests used, only unformed stools should be sent for clinical testing. Because C. 367 
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individuals diminishes the specificity of diagnosing CDI. Similarly, as people may remain 369 
colonized with C. difficile for several weeks following resolution of clinical disease, tests of cure 370 
are not indicated. (32,35) Finally, for individuals who may have an ileus, clinicians may consider 371 
sending a rectal swab, recognizing this may lead to a false-negative result.  372 
 373 
Therapy  374 
In addition to supportive care, a key step to managing CDI is, whenever possible, to stop 375 
the inciting antibiotic and avoid subsequent antibiotic exposure. Metronidazole or oral 376 
vancomycin remain the mainstays of treatment for mild to moderate disease, including 377 
recurrent episodes. (35) For people with severe CDI, treatment with oral vancomycin 378 
significantly reduced the risk of 30-day mortality (adjusted relative risk (RR), 0.79; 95% CI, 0.65 379 
to 0.97). (37) Additionally, oral vancomycin is the first-line agent for people taking warfarin. The 380 
risk of recurrent disease following treatment with metronidazole and oral vancomycin is similar. 381 
(37) While fidaxomicin appears to reduce the risk of recurrent disease, (31) the cost of this 382 
agent is several fold higher than metronidazole and oral vancomycin, the latter prepared by 383 
compounding the intravenous preparation. (35)  384 
 385 
Prevention 386 
Reducing exposure to antibiotics and to C. difficile spores are the cornerstones of CDI 387 
prevention. While any antibiotic may predispose individuals to CDI, a meta-analysis found the 388 
following agents to be high-risk: clindamycin, fluoroquinolones, cephalosporins, monobactams 389 
and carbapenems. (38) In acute and long-term care settings, ASPs reduce the incidence of CDI. 390 
(31) (See also earlier section on “Antibiotic Stewardship.) Infection prevention and control 391 
measures, discussed more extensively elsewhere, (31) seek to reduce the contamination of 392 
healthcare providers hands and the environment with C. difficile spores. While symptomatic, 393 
people with CDI should remain on contact precautions, with healthcare providers removing 394 
their gown and gloves prior to exiting the room, followed by hand washing with soap and water 395 
(alcohol gel is not sufficient to kill or remove spores). (32,35) Following resolution of symptoms, 396 
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consideration of extending contact precautions. Finally, to reduce the burden of C. difficile 398 
spores sporicidal agents approved by the environmental protective agency (EPA) should be 399 
used to clean and disinfect the equipment and environment of people with current or recent 400 
CDI. 401 
When administered concurrently with standard-of-care antibiotics, bezoltoxumab, a 402 
recently approved monoclonal antibody against C. difficile toxin B, reduced the rate of 403 
recurrent disease by 10% more than placebo. (39) Fecal microbiota transplant (FMT) has 404 
proven to be an effective and safe intervention for recurrent CDI, including among older adults. 405 
(31,35) While clinical trials are underway, vaccines against C. difficile are not yet commercially 406 
available. A systematic review of randomized controlled trials investigating probiotics found 407 
moderate quality evidence that probiotics prevent C. difficile-associated diarrhea (RR 0.36; 95% 408 
CI: 0.26, 0.51) but do not reduce the incidence of CDI (RR 0.89; 95% CI: 0.64, 1.24). While 409 
subgroup analysis to examine older adults or residents of LTCFs or to evaluate specific species 410 
or combinations of microorganisms was not feasible, the authors do conclude that probiotics 411 
are safe. (40) 412 
 413 
Norovirus 414 
Norovirus is also a common cause of gastroenteritis among long-term care residents. A 415 
recent article reviewed this topic extensively; this section will only highlight the key issues. (41) 416 
The majority of norovirus outbreaks occur in LTCFs, with 90% of norovirus-associated deaths 417 
occurring in adults ≥65 years of age. (42) Unlike CDI, norovirus infections present with acute 418 
onset nausea, vomiting and watery diarrhea. As few as 100 virions may lead to disease. Given 419 
that infected individuals may shed billions of virions in their stool and vomitus, norovirus 420 
spreads rapidly among long-term care residents and their healthcare providers. The incubation 421 
period for norovirus is 12 to 48 hours, followed by a self-limited illness that lasts 12 to 60 hours.  422 
Early recognition and prompt implementation of infection prevention and control 423 
measures are central to limiting the severity of a norovirus outbreak. Some state public health 424 
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however, LTCFs will recognize a norovirus outbreak when 2 or more cases fulfill the Kaplan 426 
Criteria:  427 
(a) vomiting in more than half of affected persons;  428 
(b) a mean (or median) incubation period of 24–48 hours;  429 
(c) a mean (or median) duration of illness of 12–60 hours; and 430 
(d) no bacterial pathogen is identified in stool culture. 431 
In LTCFs, infection prevention and control measures must address both residents and 432 
healthcare providers. Affected residents should be placed on contact precautions for at least 48 433 
hours following symptom resolution. For norovirus, contact precautions entail gowns, gloves, 434 
hand hygiene with soap and water as well as a mask when around vomitus or fecal material as 435 
norovirus may become airborne and cause infection. Additionally, the facility should minimize 436 
resident movements, suspend group activities and consider restricting access to an affected 437 
ward. Healthcare providers with symptoms consistent with norovirus infection should be 438 
excluded from work and be encouraged to stay home for 48 hours following symptom 439 
resolution. Upon returning to work, recently ill healthcare workers should care for symptomatic 440 
residents. A general framework to group residents and staff into 3 clinical categories is the 441 
following: symptomatic; asymptomatic and potentially exposed; and asymptomatic and 442 
unexposed. This framework can help with staff assignments that avoid having asymptomatic 443 
and potentially-exposed staff interact with asymptomatic and unexposed residents.  444 
 445 
Clinical Relevance 447 
BACTERIAL PNEUMONIA 446 
Infections of the lower respiratory tract, which include pneumonia and bronchitis, are 448 
leading causes of morbidity and mortality among older adults. Pneumonia, in particular, affects 449 
1.4 to 2.5% of nursing home residents in the United States and is among the most common 450 
causes for hospitalization. (43) Age-related changes to the respiratory system, including 451 
diminished cough and gag reflexes, impaired mucocilary clearance, reduced respiratory muscle 452 
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defense mechanisms and allow pathogens to penetrate and infect the respiratory tract. This 454 
section will focus on only bacterial pneumonia.  455 
Recognition, diagnosis and treatment of acute infections of the lower respiratory tract 456 
among LTCF residents present significant challenges. Co-morbid conditions including congestive 457 
heart failure and chronic respiratory diseases may confound the clinical presentation. 458 
Additionally, aspiration of oral contents into the respiratory tract may lead to chemical 459 
pneumonitis or bacterial pneumonia or both. Furthermore, while the vast majority of people 460 
with acute bronchitis have a viral infection, some of them may go on to develop secondary 461 
bacterial pneumonia. Recent evidence implicates a viral pathogen in at least 25% of older adults 462 
presenting with community-acquired pneumonia. (44) While the implications on the treatment 463 
of older adults with pneumonia, particularly those who are LTCF residents, are not yet known, 464 
these data help to explain the similarity in clinical predictors for pneumonia due to bacterial, 465 
viral and mixed etiologies. (45) Finally, the high rate of colonization with MDROs among LTCF 466 
residents in general, coupled with a paucity of microbiological data from the individual resident 467 
in whom there is a concern for bacterial pneumonia, render selection of appropriate empirical 468 
antimicrobial therapy challenging.  469 
 470 
Clinical Presentation 471 
Clinical indicators of bacterial pneumonia include fever, pleuritic chest pain, respiratory 472 
rate of >25 breaths per minute, a decline in functional status, new or increased cough, sputum 473 
production, shortness of breath, or physical findings upon examination of the chest. A 474 
retrospective review of nearly 300 nursing home residents admitted through the emergency 475 
room with a diagnosis of pneumonia described dyspnea as the most common presenting 476 
symptom (67%), followed by mental status change (51%), cough (49%) and fever (45%). (46) In 477 
another study, the authors reported on an attempt to develop a consensus of characteristics 478 
for the diagnosis of pneumonia among nursing home residents. Of the pulmonologists and 479 
geriatricians queried, 57% agreed that dyspnea, fever, decline in functional status, tachypnea, 480 
and crackles or rales on auscultation were important characteristics; they further agreed that at 481 
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pneumonia. For aspiration pneumonia, 80% of the clinicians reached a consensus of the 483 
following as risk indicators for aspiration pneumonia: dysphagia, choking incident, tube feeding, 484 
neurological disease and cognitive impairment. (47) However, with advanced age and decline in 485 
functional capacity the presence of typical pneumonia symptoms decreases. Accordingly, 486 
atypical symptoms (e.g., change in mental status, loss of appetite) or an exacerbation of chronic 487 
illnesses (e.g., congestive heart failure, chronic respiratory illness, diabetes mellitus) may be 488 
early clinical indicators of an acute infection, including pneumonia.  489 
 490 
Diagnostic Approach 491 
In addition to assessing clinical changes, the diagnostic evaluation of an LTCF resident 492 
with suspected bacterial pneumonia should include measuring pulse oximetry and obtaining a 493 
chest radiograph. Among LTCF residents, demonstration of deceased oxygen saturation using a 494 
bedside pulse oximeter may suggest pneumonia. A case-control study of residents in a 495 
veteran’s nursing home found that a decrease in oxygen saturation of >3% from baseline or 496 
<94% suggested pneumonia. (48) Chest radiographs revealing a new infiltrate also indicate 497 
pneumonia. Obtaining a chest radiograph of sufficient quality to make this determination, 498 
however, may be challenging in LTCF settings due to the limitations of portable films, inability 499 
of an ill resident to maintain a suitable position, and interpretation including delays or lack of 500 
comparative radiographs. Interestingly, in the study of patients hospitalized for nursing 501 
home-acquired pneumonia, the authors found that fewer than 20% of chest radiographs 502 
obtained in the emergency department indicated possible pneumonia. (46) These data suggest 503 
during the initial phase of illness, a “negative” chest radiograph is not sufficient to exclude a 504 
lower respiratory tract infection.  505 
While consistently challenging to obtain and, sometimes to interpret, sputum culture 506 
results, the findings can help direct appropriate antibiotic therapy. A study found that among 507 
56 patients hospitalized with nursing home-acquired pneumonia, microbiological culture results 508 
were available for just 12% of cases. (49) This unfortunate paucity of sputum cultures increases 509 
the necessity of using rapid diagnostic tests. Positive tests for Streptococcus pneumoniae 510 
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therapeutic agent and length of therapy used to treat LTCF residents. Similarly, multiplex panels 512 
that test for several respiratory pathogens may help improve the diagnosis of bacterial 513 
pneumonia though their cost makes routine use of these impractical for most LTCF settings. 514 
Finally, while procalcitonin holds the potential to identify bacterial infections, further studies 515 
are needed to understand if this test has a role in the clinical evaluation of frail older adults or 516 
LTCFs residents with suspected pneumonia.  517 
 518 
Therapy 519 
The Loeb Minimum Criteria offer a concise set of recommendations for starting 520 
antibiotic treatment in LTCF residents in whom there is a concern for bacterial pneumonia. (28) 521 
Evidence-based recommendations for empirical agents and length of therapy are less clear. 522 
Despite the prevalence of MDROs colonizing LTCF residents, recent literature suggests that 523 
using antibiotics recommend for community-acquired pneumonia are sufficient to treat most 524 
cases of nursing-home acquired pneumonia (Table 3). (46,50) While few data specifically 525 
address older adults or LTCF residents with bacterial pneumonia, recommendations for treating 526 
community-acquired and hospital-acquired pneumonia indicate that in most instances the 527 
length of antibiotic therapy should be 5-7 days. (51,52) In general, short, fixed course of 528 
antibiotics reduce adverse events related to antibiotics, including CDI, the emergence of 529 
resistant bacteria and costs, without reducing the benefits of antibiotic therapy. For residents 530 
with immunocompromising conditions, structural lung disease or a delayed response to 531 
empirical therapy, a longer course of antibiotics (i.e., 7 to 10 days) may be warranted. 532 
Hospitalization should be considered in those residents with respiratory compromise, 533 
cardiovascular instability, worsening of pre-existing non-infectious comorbidities or poor oral 534 
intake or inadequate nutrition.  535 
 536 
Prevention  537 
Vaccination against S. pneumoniae and influenza remain central to reducing the risk of 538 
lower respiratory tract infection among LTCF residents. While dysphagia is clearly a risk factor 539 
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aspiration have not reduced the incidence of respiratory illness. (53) (See section on 541 
Preventative Interventions for a more detailed discussion.) 542 
 543 
URINARY TRACT INFECTION 544 
Clinical Relevance 545 
UTI is one of the most common infections diagnosed in residents of LTCFs. (54) The high 546 
frequency of infection is largely attributable to comorbidities which affect normal voiding, such 547 
as urologic abnormalities and chronic neurologic diseases. A very high prevalence of 548 
asymptomatic bacteriuria, i.e., 35-50% of residents without indwelling urethral catheters, also 549 
occurs in this population. While asymptomatic bacteriuria is benign, the common finding of a 550 
positive urine culture leads to frequent overdiagnosis of symptomatic UTI. As many as 75% of 551 
prescriptions for UTI in LTCF residents are given to individuals who do not meet criteria for UTI. 552 
(55) This is a major contributor to inappropriate antimicrobial use in long-term care, and 553 
promotes antimicrobial resistance and CDI in residents. (55,56) The important clinical issues for 554 
optimizing management of UTI are the ascertainment of symptomatic infection and 555 
non-treatment of asymptomatic bacteriuria. 556 
From 5-10% of residents in LTCFs have bladder emptying managed with a chronic 557 
indwelling catheter. (57) Bacterial biofilm formation along the internal and external catheter 558 
surfaces is universal, so polymicrobial bacteriuria is the norm for residents with chronic 559 
catheters. The presence of a catheter is associated with an increased incidence of symptomatic 560 
UTI, and catheter-associated UTI (CAUTI) is the most frequent source of bacteremia in LTCFs. 561 
(54,57)  562 
 563 
Clinical Presentation 564 
Residents with UTI may present with typical clinical symptoms. (54) Bladder infection is 565 
manifested by an acute onset of lower tract irritative symptoms of frequency, urgency, slow 566 
and painful urination (stranguria), dysuria or new or increased incontinence. Upper tract 567 
(kidney) infection presents as pyelonephritis with costovertebral angle pain or tenderness, 568 
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symptoms in many residents, however, is problematic because of impaired communication, 570 
functional disability, and chronic genitourinary symptoms attributed to comorbidities. (24,54) 571 
Residents without acute localizing genitourinary findings but with clinical deterioration and 572 
nonspecific symptoms or signs are frequently diagnosed and treated as UTI, often because a 573 
urine culture is positive. (24,54-56) However, evidence does not support attributing 574 
nonlocalizing and nonspecific symptoms to UTI, even with a positive urine culture. (24,58) 575 
Mental deterioration (e.g., delirium) (59) or falls (60), by themselves, are generally not 576 
presentations of UTI. 577 
Residents with CAUTI usually present with fever alone, although localizing symptoms 578 
including catheter obstruction, acute hematuria, or suprapubic or costovertebral tenderness 579 
may occasionally be present. (57) Determinants of symptomatic infection are not well 580 
described, but catheter obstruction or catheter trauma are potential antecedents of 581 
symptomatic infection.  582 
 583 
Diagnostic Approach 584 
Guidelines for diagnosing symptomatic UTI in residents without indwelling catheters 585 
require the presence of localizing genitourinary symptoms or signs (24,28,29,54) (Table 4). An 586 
evidence-based diagnostic approach to UTI was recommended in the 2009 Infectious Diseases 587 
Society of America (IDSA) guidelines for evaluation of fever and infection in older adult 588 
residents of LTCFs. (29) For residents in whom a diagnosis of UTI is considered, a urine 589 
specimen for determination of pyuria should be obtained. If a voided urine specimen cannot be 590 
collected, an in-and-out catheter specimen should be collected, whenever possible. A urine 591 
culture is requested only if the urinalysis is positive. A screening test for pyuria has a negative 592 
predictive value of over 95% for UTI, so UTI is excluded if pyuria is not present. (29) However, 593 
pyuria accompanies asymptomatic bacteriuria, and is also found in as many as 30% of residents 594 
without bacteriuria. Thus, pyuria, by itself, does not diagnose bacteriuria or differentiate 595 
symptomatic from asymptomatic infection. (54)  596 
The most common clinical presentation of CAUTI is fever alone (Table 4). When fever is 597 
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the catheter is recommended if it has been present for 2 weeks or more, as the biofilm 599 
contaminates a urine specimen collected through the catheter. Obtaining a urine specimen 600 
through a freshly inserted catheter provides a more valid specimen to identify bladder 601 
bacteriuria and infecting organisms and susceptibilities. (57) Blood cultures are indicated for 602 
patients with or without catheters who are severely ill. Residents with indwelling catheters are 603 
more likely to experience urosepsis. 604 
Some residents present with a clinical syndrome consistent with severe sepsis, 605 
including one or more of the following signs: 
 610 
fever or hypothermia, hemodynamic instability, 606 
acute delirium, and respiratory distress. If no source for infection is apparent, these patients 607 
should be managed appropriately as sepsis syndrome, considering urinary infection as one 608 
potential site, pending results of cultures and other investigations.  609 
Therapy 611 
When the presenting symptoms are mild, initiation of antimicrobial therapy should 612 
await urine culture results. If the urine culture is subsequently positive, antimicrobial therapy 613 
should only be initiated if symptoms have persisted. When fever alone is present in residents 614 
with chronic indwelling catheters, clinical monitoring without initiation of antimicrobial therapy 615 
may also be appropriate. As many as two-thirds of febrile episodes in residents with long-term 616 
catheters are attributed to urinary infection, but most resolve in less than 24 hours without 617 
intervention. (61) In patients with severe symptoms including sepsis, immediate empirical 618 
therapy is indicated. Asymptomatic bacteriuria should be treated only prior to an invasive 619 
urologic procedure which is likely to be associated with mucosal bleeding. A single dose of an 620 
effective antimicrobial given immediately prior to the procedure is usually effective for 621 
prophylaxis. (54)  622 
The choice of antimicrobial regimen, including oral or intravenous therapy and duration, 623 
is determined by consideration of the clinical presentation, resident tolerance, and known or 624 
suspected susceptibilities of the infecting organism. (54) Susceptibility of organisms isolated in 625 
prior urine cultures from the resident and the resistance prevalence of uropathogens in the 626 
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similar to other populations with UTI and may include, nitrofurantoin (for cystitis only), 628 
trimethoprim/sulfamethoxazole, ampicillin, cephalexin and, when indicated, fluoroquinolones, 629 
oral extended-spectrum cephalosporins, or amoxicillin/clavulanic acid. (54) Where resistant 630 
organisms are isolated, antimicrobial selection is directed by susceptibility, and 631 
aminoglycosides, carbapenems and beta- lactam/beta-lactamase inhibitor combinations may 632 
be appropriate. For residents requiring parenteral therapy, transfer to an acute care facility 633 
may be necessary. 634 
 635 
Prevention 636 
For residents with frequent recurrent symptomatic infection, especially when the 637 
clinical presentation is severe, urologic abnormalities, which are potentially correctable, such as 638 
obstruction, should be excluded. Prophylactic antimicrobial therapy for women or men with 639 
recurrent infection should be avoided, as this promotes emergence of resistant organisms 640 
without decreasing the frequency of symptomatic infection. Cranberry products do not 641 
decrease the frequency of infection. (62) The most effective means of preventing CAUTI is to 642 
remove the catheter, whenever possible. When this is not possible, resident care practices to 643 
identify catheter obstruction early and to avoid trauma to the catheter should be implemented 644 
and followed.  645 
 646 
PREVENTIVE INTERVENTIONS  647 
Clinical Relevance 648 
Similar to cardiovascular disease and cancer prevention is key to reducing the risk of 649 
infection, particularly in LTCFs, which have a high prevalence of MDROs. Administration of 650 
influenza vaccine to older adults as well as healthcare personnel lowers infection rates, saves 651 
lives, and reduces complications. (63) Recommended vaccinations in older adults include yearly 652 
influenza vaccine, 1 dose of pneumococcal conjugate vaccine (PCV13) and at least one dose of 653 
pneumococcal polysaccharide vaccine (PCV23), herpes zoster vaccine, and tetanus-diphtheria 654 
and acellular pertussis (Tdap) vaccine if there is anticipated contact with a child less than 12 655 
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management of chronic diseases; prevention of pressure ulcers; attention to infection 657 
prevention practices, such as hand hygiene for healthcare professionals, caregivers, patients 658 
and families; appropriate gown and glove use; and judicious antibiotic usage, are all key 659 
preventive measures to reduce infections and enhance quality of care among older adults in 660 
NFs.  661 
 662 
Emerging Evidence 663 
Several recent randomized controlled trials identify preventive interventions that are 664 
shown to be of benefit and help discard those that are not. Next, we provide a brief overview of 665 
some recent studies. 666 
 667 
UTIs 668 
Use of Cranberry to Prevent UTIs 669 
In a recent randomized controlled study, investigators asked the question: Do two oral 670 
cranberry caps/day lead to lower bacteriuria plus pyuria among non-catheterized older women 671 
in NFs? (62) In a double blind, placebo-controlled randomized controlled trial focused on older 672 
long-term female residents, consenting participants were randomized to two cranberry 673 
capsules per day (equivalent to 72mg of proanthocyanidins) versus placebo for 360 days. 674 
Surrogate consent was required in 94% of the instances highlighting challenges in conducting 675 
research in these settings. Twenty-six percent of urine specimens in the treatment group and 676 
30% of urine specimens in the control group had pyuria with bacteriuria. In other words, 677 
cranberry capsules did not have any effect on the primary outcome. Furthermore, cranberry 678 
capsules had no impact on secondary outcomes. This study helped discard long-held pervasive 679 
practice of using cranberry capsules to prevent UTI. (64)
 680 
 681 
Bundled Approach to Preventing CAUTI  682 
In a recent cluster-randomized interventional study, investigators evaluated the effect 683 
of a Targeted Infection Prevention (TIP) multi-modal intervention program in reducing MDRO 684 
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intervention included a structured interactive educational program for frontline healthcare 686 
personnel, hand hygiene promotion, preemptive barrier precautions when assisting with 687 
high-risk activities of daily living (e.g., bathing, dressing, grooming, toileting, feeding, and 688 
ambulation), and active surveillance for MDROs and infections with monthly data feedback. 689 
Interactive educational modules, incorporating Adult Learning Theory, were presented to 690 
healthcare personnel at intervention sites through 10 in-services on a broad range of topics, 691 
including overview of infection prevention practices, hand hygiene, barrier precautions, 692 
infection recognition, and care of indwelling devices, with content following evidence-based 693 
guidelines. This approach was shown to reduce overall MDRO prevalence by 23%, new MRSA 694 
acquisition by 22% and clinician-diagnosed CAUTIs by 31%. (65)  695 
Lessons learned from the TIP study as well as the “Agency for Healthcare Research and 696 
Quality (AHRQ) Safety Program for Reducing Catheter-associated UTI in Hospitals” (66) were 697 
then implemented in nearly 500 NHs in 48 states through the “ARHQ Safety Program in 698 
Long-Term Care: HAI/CAUTI” project. (67) Using a combination of technical and socio-adaptive 699 
interventions, the program emphasized professional development in urinary catheter 700 
utilization, catheter care and maintenance, and antimicrobial stewardship, as well as promoting 701 
NF resident safety culture, team building, and leadership engagement. CAUTI rates decreased 702 
by 54% (incidence rate ratio (IRR), 0.46; 95% CI, 0.36-0.58; P<.001) during the project. The 703 
number of urine cultures ordered for all residents decreased by 15%. (67) 704 
 705 
Respiratory Tract Infections 706 
Use of High-Dose Vitamin D in Pneumonia Prevention 707 
In another recent randomized controlled study, investigators conducted a major 708 
randomized controlled trial to determine the efficacy and safety of high-dose vitamin D to 709 
prevent acute respiratory tract infections in NHs. (68) The study involved 25 Colorado-based 710 
NFs and residents over the age of 60. Participants were randomized to a high-dose group that 711 
received 100,000 international units (IU) of vitamin D monthly and a standard dose group that 712 
received either placebo if already on supplementation of 400-1,000 IU/d of vitamin D or 12,000 713 
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respiratory tract infections/year, standard-dose group experienced 0.6 infections/year and the 715 
difference being clinically insignificant. Furthermore, falls were more common in high-dose 716 
group at 1.47/person-year versus standard-dose group at 0.63/person-year. However, fractures 717 
were uncommon. Thus, the role of high-dose Vitamin D in preventing infections remains 718 
unclear. 719 
 720 
Chlorhexidine-based Oral Care in Aspiration Pneumonia  721 
Several preliminary studies suggest that adequate oral hygiene using mouth rinses, toothpaste, 722 
brushing along with feeding in an upright position, would mitigate the risk of pneumonias 723 
attributed to aspiration. (53) In another major cluster-randomized study involving 36 NFs in 724 
Connecticut, the study involved older NF residents with at least one of the two following 725 
modifiable risk factors: impaired oral hygiene or swallowing difficulty by clinical assessment. 726 
The intervention comprised of manual tooth/gum brushing along with a chlorhexidine rinse 727 
twice a day along with upright positioning. Primary and secondary outcomes included time to 728 
first chest radiograph confirmed pneumonia and development of first lower respiratory tract 729 
infections, respectively. However, with the adjusted hazard ratio of 1.12 (95% CI 0.84, 1.5, p 730 
0.44) for the primary outcome of time to first pneumonia, the study was terminated for futility 731 
and ineffectiveness, since this chlorhexidine-based intervention was not effective in reducing 732 
lower respiratory infections and thus questioning the utility of this particular enhanced oral 733 
care protocol in long-term populations.  734 
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TABLES 950 
Table 1. Core Elements of Antibiotic Stewardship in Nursing Facilities (12).  951 




and commitment to 
safe and 
appropriate 
antibiotic use in the 
facility. 
 
• Medical director and nursing leadership 
should provide visible support for the facility 
antibiotic stewardship program (ASP). 
• Leader of ASP should have dedicated time to 
perform their stewardship duties. 
• Structure, roles and responsibilities of facility 
ASP should be clearly delineated in a policy 
that is reviewed and approved by facility 
leadership. 
• The facility ASP should periodically report to 
the facility Quality Assurance and 
Performance Improvement (QAPI) committee 
2. Accountability Identify which 
members of the 
facility will be part 
of the stewardship 
team and clearly 
delineate their role 




leadership of the 
stewardship team to 
• Antibiotic stewardship is a team-based 
process that requires involvement and 
collaboration between leadership, providers, 
nursing staff and pharmacy. 
• While responsibility for completing various 
ASP tasks may be delegated to different 
members of the team, administrative 
oversight should be assigned to a single 
individual. 
• The ASP team leader should have a clinical 
background plus a demonstrated capacity to 
work and communicate well with 
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a single individual. 
 
in the facility. 
3. Drug Expertise Ensure access to 
individuals with 
experience and/or 
training in antibiotic 
stewardship. 
 
• Ideally, the individual selected to lead the 
facility stewardship team will have prior 
training/expertise in infectious diseases 
and/or antibiotic stewardship but this will be 
unusual in most nursing facilities.  
• In the absence of local expertise, the facility 
should: 
⇒ Provide support for the stewardship team 
to attend stewardship training 
opportunities and pursue formal 
certification, if available. 
⇒ Identify and collaborate with experts in 
the region (e.g., referring acute care 
hospital) who can help develop facility 
policies/guidelines and provide input on 
selection and implementation of different 
stewardship interventions. 
4. Action Implement at least 
one policy or 
practice to improve 
antibiotic use in the 
facility. 
 
• Specific strategies should be chosen based on 
facility resources and needs identified 
through tracking measures. 
• Strategies that focus on reducing unnecessary 
testing of urine samples and treatment of 
asymptomatic bacteriuria appear to have the 
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antibiotic use in the 
facility. 
• At a minimum, track facility-initiated 
antibiotic starts on a monthly basis (ideally, 
denominate by resident-days). 
Other utilization measures to consider 
include, proportion of antibiotic starts 
prescribed for >7 days and proportion of 
antibiotic starts that meet appropriateness 
criteria.  
• Clinical outcomes that should be considered 
include the monthly number of residents 
colonized or infected with different 
multidrug-resistant organisms (e.g., 
methicillin-resistant Staphylococcus aureus), 
Clostridium difficile, and the facility 
antibiogram.  
6. Reporting Provide regular 
feedback of 
antibiotic use and 
antibiotic resistance 
to staff and 
providers in the 
facility. 
 
• Antibiotic utilization and clinical outcomes 
data should be presented at least quarterly at 
the facility QAPI meeting. 
• Providing individual feedback to providers on 
their prescribing patterns relative to their 
peers may have a beneficial normative 
influence on outliers.  
7. Education Provide resources to 
staff, providers and 
patients/residents 
about the risks of 
• Education on the importance of antibiotic 
stewardship and the strategies the facility is 
using to promote better antibiotic 























• Education should target both nursing staff 
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Table 2. Empirical Treatment for Skin and Soft Tissue Infections in Long-Term Care Residents. 953 
 954 
PRIMARY BACTERIAL INFECTIONS 955 
__________________________________________________________________________________________________________________________________ 956 
Impetigo (non-bullous and bullous) 957 
__________________________________________________________________________________________________________________________________ 958 
Severity Route  Antimicrobials Minimum Duration Typical Organisms  Comments 959 
__________________________________________________________________________________________________________________________________ 960 
Mild oral dicloxacillin or 7 days Staphylococcus aureus if many lesions 961 
  cephalexin  MSSA most common empiric Rx 962 
 963 
  doxycycline or  MRSA culture known 964 
  clindamycin or 965 
  TMP/SMX 966 
 967 
  penicillin  GABHS culture known 968 
 969 
 topical mupirocin 5 days streptococci, S. aureus empirical Rx 970 
__________________________________________________________________________________________________________________________________ 971 
Non-purulent infections (cellulitis, erysipelas, necrotizing infection) 972 
 973 
Mild* oral penicillin or 5 days streptococci cultures; aspirates not 974 
 dicloxacillin or    routinely recommended 975 
 cephalosporins or 976 
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 978 
Moderate** IV penicillin or  streptococci consider MSSA Rx; 979 
  ceftriaxone or  consider MRSA Rx  980 
  cefazolin or if prior infection 981 
  clindamycin 982 
 983 
Severe*** IV vancomycin GABHS transfer to hospital; 984 
  piperacillin/tazobactam polymicrobial emergent surgery; 985 
   deep tissue culture 986 
 987 
Purulent infections (furuncle, carbuncle, abscess) 988 
 989 
Mild+ N/A none N/A S. aureus incision & drainage; 990 
   MSSA, MRSA antibiotics if fails 991 
 992 
Moderate++ oral TMP/SMX or minimum 5 days S. aureus incision & drainage; 993 
  doxycycline  MSSA, MRSA culture & susceptibility 994 
   995 
 IV/oral glycopeptides or 996 
  daptomycin or 997 
  ceftaroline or 998 
  linezolid 999 
 1000 
Severe+++ IV as above N/A S. aureus transfer to hospital; 1001 
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   deep tissue culture 1003 
Necrotizing fasciitis/gangrene 1004 
 1005 
Severe IV vancomycin & N/A polymicrobial transfer to hospital; 1006 
  piperacillin/tazobactam  S. pyogenes emergent surgery; 1007 
  vancomycin & carbapenem or S. aureus deep tissue culture 1008 
  vancomycin & metronidazole & 1009 
  ceftriaxone 1010 
Pyomyositis 1011 
 1012 
Severe IV vancomycin N/A S. aureus transfer to hospital; 1013 
    MSSA/MRSA emergent imaging; 1014 
deep tissue & blood culture 1015 
__________________________________________________________________________________________________________________________________ 1016 
SECONDARY BACTERIAL INFECTIONS 1017 
__________________________________________________________________________________________________________________________________ 1018 
Surgical Site Infection > 4 days post-operatively 1019 
__________________________________________________________________________________________________________________________________ 1020 
 1021 
Clean Site IV vancomycin or N/A S. aureus erythema > 5 cm from  1022 
head, neck  cefazolin   MSSA/MRSA incision; T > 38°C;  1023 
trunk, extremity       elevated WBC; 1024 
        begin dressing changes 1025 
Perineal wound or IV cephalosporin &   polymicrobial 1026 
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   levofloxacin & 1028 
   metronidazole or 1029 
   carbapenem 1030 
 1031 
Pressure Ulcer Infection: Stage III or IV 1032 
__________________________________________________________________________________________________________________________________ 1033 
 1034 
  PO ciprofloxacin or levofloxacin & polymicrobial optimize local care; 1035 
   metronidazole or clindamycin aerobes &  debride necrotic tissue; 1036 
     anaerobes deep tissue for culture; 1037 
       osteomyelitis evaluation 1038 
 1039 
  IV piperacillin-tazobactam or 1040 
   carbapenem or 1041 
   cephalosporin & metronidazole 1042 
   or clindamycin 1043 
   quinolone & metronidazole or 1044 
   clindamycin 1045 
 1046 
   if MRSA suspected, add vancomycin 1047 
 1048 
 1049 
Superficial fungal infections 1050 
 1051 
















This article is protected by copyright. All rights reserved 
vaginitis  or
thrush  oral fluconazole, itraconazole     common with azoles; 1054 
      drug interactions are  1053 




tinea pedis topical clotrimazole, terbinafine   dermatophytes drug interactions are 1059 
tinea capitis or
tinea ungiuum oral itraconazole, terbinafine     monitor hepatotoxicity 1061 
      common with azoles; 1060 
tinea cruris      1062 
 1063 
Herpesviruses  1064 
 1065 
Shingles  IV  acyclovir   varicella zoster virus VZV higher doses than HSV 1066 
 oral acyclovir, famciclovir   (VZV) IV for disseminated  1067 
  valaciclovir    infection 1068 
        adjust for renal function 1069 
        treat VZV-related PHN 1070 
  1071 
Genitorectal herpes oral acyclovir, famciclovir   herpes simplex virus  adjust for renal function 1072 
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 oral ivermectin     crusted scabies 1078 
 1079 
Lice topical permethrin % 12 hours   retreat one week later 1080 
       1081 
      1082 
 1083 
Bedbugs N/A N/A NA   contact precautions 1084 
       launder clothing 1085 
       contact isolation 1086 
       disinfect mattress 1087 
       seek expert guidance 1088 
 1089 
 1090 
Adapted from (25-27) 1091 
 1092 
MSSA = Methicillin-susceptible S. aureus 1093 
MRSA = Methicillin-resistant S. aureus 1094 
GABHS = group A beta-hemolytic streptococci 1095 
TMP-SMX = trimethoprim-sulfamethoxazole 1096 
IV = intravenous 1097 
WBC = white cell count 1098 
GI/GU = gastrointestinal/genitourinary 1099 
 1100 
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Mild* typical cellulitis /erysipelas without focus of purulence 1104 
Non-purulent Severity Index 1103 
Moderate** typical cellulitis/erysipelas with systemic signs of infection 1105 
Severe*** residents who have failed oral therapy with systemic signs of infection, who are immunocompromised, or have signs of deeper 1106 
infection such as bullae, skin sloughing, hypotension, or organ dysfunction 1107 
Mild+ purulent infection 1109 
Purulent Severity Index 1108 
Moderate++ purulent infection with systemic signs of infection 1110 
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Table 3: Suggested Empirical Antibiotic Therapy for Nursing Home-Acquired Bacterial 1114 
Pneumonia. 1115 
Clinical Context First-line Second-Line  
Mild to moderate pneumonia 
symptoms 
- cefpodoxime or 
- amoxicillin/clavulanic acid (first 
choice if aspiration suspected) 
- doxycycline or 
- levofloxacin 
Severe pneumonia symptoms 
or failure to improve with 
appropriate empirical therapy 
 
- ceftriaxone and azithromycin 
- ertapenem or 
- levofloxacin  
Severe pneumonia symptoms and 
concern for MRSA in respiratory 
tract 
- consider adding vancomycin or 
doxycycline 
 - consider adding linezolid  
Known history or strong suspicion 
of Pseudomonas or resistant 
Gram-negative bacteria in 
respiratory tract 
- cefepime or 
- piperacillin/tazobactam 
- levofloxacin or 
- carbapenem (other than 
ertapenam) or 
- aztreonam  
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Table 4: Guidelines Providing Criteria for the Clinical Diagnosis of Urinary Tract Infection (UTI) in Residents of Long-Term Care 1117 
Facilities (LTCFs).  1118 
 1119 
Reference Proposed Use Residents without indwelling catheters Residents with indwelling catheters 
Loeb et al, (28) Minimum criteria for 
the initiation of 
antibiotic therapy for 
urinary infection  
Acute dysuria alone, or fever [> 37.9°C 
(100°c) or 1.5°C (2.4°F) above baseline] 
and one or more of: new or worsening 
urgency, frequency, suprapubic pain, gross 
hematuria, costovertebral angle 
tenderness, or urinary continence.   
Presence of at least one of the following: 
• Fever (>37.9°C or 1.5°C above baseline) 
• New costovertebral angle tenderness, 
rigors (shaking, chills) with or without 
identified cause, 
• New onset delirium 
High et al, (29) Evaluation of fever 
and infection in older 
residents of LTCFs. 
Acute onset of UTI associated symptoms 
and signs (e.g., fever, dysuria, gross 
hematuria, new or worsening urinary 
incontinence, and/or suspected 
bacteremia). 
Suspected urosepsis (i.e., fever, shaking, 
chills, hypotension or delirium), especially 
in the context of recent catheter 
obstruction or change. 
Stone et al, (24) Surveillance 
definitions for 
infection in long term 
care. 
At least one of the following symptoms or 
signs:  
a) acute dysuria or acute pain, swelling or 
tenderness of the testes, epididymis or 
prostate.   
b) Fever or leukocytosis [single oral 
At least one of the following signs or 
symptoms: 
a) Fever, rigors, or new onset of 
hypotension with no alternate source of 
infection 
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temperature > 37.8°C (>100°F), or 
repeated oral temperature >37.2°C 
(99°F) or rectal temperatures >37.5°C 
(99.5°F or single temperature ≥1.1°C 
(2°F) over baseline from any site]; 
leukocytosis, neutrophila (>14,000 
leukocytes/cubic mm) or left shift (>6% 
bands or 1,500 bands/cubic mm)] and 
at least one of the following localizing 
subcriteria: 
1. Acute costovertebral angle pain or 
tenderness; 2. Suprapubic pain;     
3. Gross hematuria; 4. New or 
marked increasing incontinence or 
urgency or frequency; 5. Urgency 
c) In the absence of fever or leukocytosis, 
then two or more of the above 
localizing urinary tract sub-criteria. 
acute functional decline, with no 
alternate diagnosis and leukocytosis 
c) New onset suprapubic pain or 
costovertebral angle pain or tenderness 
d) Purulent discharge from around the 
catheter or acute pain, swelling or 
tenderness of the testes, epididymis or 
prostate 
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